---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-064509"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:07:45.410973+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Sagimet Biosciences updates investor presentation; no new material data disclosed

## Summary
- Filed an updated slide presentation as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure.
- Presentation titled 'Targeting Metabolic Dysfunction with Novel Therapies to Treat MASH, Acne and Cancer' dated May 2024.
- No specific financial or clinical data from the presentation were provided in the filing text.

## SEC filing metadata
- accession: 0001104659-24-064509
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924064509/0001104659-24-064509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924064509/tm2415356d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-064509
- JSON: https://secwatch.observer/filing/0001104659-24-064509.json
- Plain text: https://secwatch.observer/filing/0001104659-24-064509.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.